Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VICTORIA A STATLER

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1770604191
CMS profile
1239227
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$5,500.00

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $3,500.00 1
Consulting Fee $2,000.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Seqirus USA Inc $5,500.00 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VICTORIA A STATLER

NPI 1770604191 · CMS profile ID 1239227

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770604191?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VICTORIA A STATLER, NPI 1770604191, CMS profile ID 1239227. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770604191?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). VICTORIA A STATLER, NPI 1770604191, CMS profile ID 1239227. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770604191?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
VICTORIA A STATLER, NPI 1770604191, CMS profile ID 1239227, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1770604191?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $5,500.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Seqirus USA Inc $2,000.0008/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820572583 CMS
Seqirus USA Inc $3,500.0005/12/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820572577 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $485.74 1
PY2021 $5,500.00 2
PY2022 $2,450.00 5
PY2023 $2,162.77 4
PY2024 $4,326.00 2
PY2025 $1,241.86 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $89,965.23 2
PY2024 Principal investigator $56,359.42 4
PY2023 Principal investigator $17,015.00 3
PY2022 Principal investigator $28,796.43 7
PY2021 Recipient $198.26 2
PY2021 Principal investigator $33,032.43 42
PY2020 Recipient $2,869.17 11
PY2020 Principal investigator $78,870.85 49
PY2019 Recipient $537.78 2
PY2019 Principal investigator $83,019.90 45

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $14.93 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE PEDIATRIC CLINICAL TRIALS UNIT
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 848761785
Principal investigator 1 PFIZER INC. $5,704.40 12/21/2021 Non-covered Recipient Entity
University of Louisville Research Foundation Inc
A PHASE 4 OPENLABEL SINGLEARM TRIAL TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TRUMENBAREGISTERED WHEN ADMINISTERED TO IMMUNOCOMPROMISED PARTICIPANTS 10 YEARS OF AGE No dispute reported 06/30/2026 832565389
Principal investigator 1 SANOFI PASTEUR INC. $760.00 12/17/2021 Non-covered Recipient Entity
University Of Louisville Hospital
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838375141
Principal investigator 1 Gilead Sciences, Inc. $1,580.00 11/17/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 803519973
Principal investigator 1 SANOFI PASTEUR INC. $660.00 11/17/2021 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838375125
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054815
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054817
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054819
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054821
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054825
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054827
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054829
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054831
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054839
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054841
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054843
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054845
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054855
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054857
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054859
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054861
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054873
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054875
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054877
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054879
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054889
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054891
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054893
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054895
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054909
Principal investigator 1 Astellas US Technologies $324.85 11/04/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 775054911
Principal investigator 1 SANOFI PASTEUR INC. $1,520.00 10/27/2021 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838375117
Principal investigator 1 Gilead Sciences, Inc. $750.00 09/08/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 803519971
Principal investigator 1 SANOFI PASTEUR INC. $442.00 08/25/2021 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838375037
Principal investigator 1 SANOFI PASTEUR INC. $970.00 07/19/2021 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838374987
Recipient Astellas Pharma Global Development $99.13 06/23/2021 Covered Recipient Physician A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients No dispute reported 06/30/2026 801078519
Principal investigator 1 SANOFI PASTEUR INC. $970.00 06/04/2021 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838374958
Principal investigator 1 Gilead Sciences, Inc. $1,580.00 05/19/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 803519967
Principal investigator 1 Gilead Sciences, Inc. $2,835.00 05/19/2021 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 803519969
Principal investigator 1 SANOFI PASTEUR INC. $1,940.00 04/28/2021 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838374931
Recipient Astellas Pharma Global Development $99.13 04/27/2021 Covered Recipient Physician A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients No dispute reported 06/30/2026 801078517
Principal investigator 1 SANOFI PASTEUR INC. $1,500.00 03/19/2021 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838374917
Principal investigator 1 SANOFI PASTEUR INC. $2,700.00 03/05/2021 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838374909
Principal investigator 1 SANOFI PASTEUR INC. $660.00 01/19/2021 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838374851